NCT02302079View on ClinicalTrials.gov

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 12, 2015

Primary Completion Date

August 12, 2016

Study Completion Date

August 12, 2016

Conditions
Diabetes MellitusDiabetic Macular Edema
Interventions
DRUG

ASP8232

oral capsule

DRUG

ranibizumab

intravitreal (IVT) injection

DRUG

Placebo

oral capsule

OTHER

Sham intravitreal (IVT) injection

intravitreal (IVT) injection

Trial Locations (21)

22903

Site US10017, Charlottesville

30909

Site US10036, Augusta

33126

Site US10016, Miami

33880

Site US10005, Winter Haven

37203

Site US10012, Nashville

77030

Site US10013, Houston

78503

Site US10030, McAllen

78705

Site US10015, Austin

79606

Site US10010, Abilene

80401

Site US10029, Golden

85104

Site US10021, Phoenix

85704

Site US10025, Tucson

89511

Site US10027, Reno

90211

Site US10004, Beverly Hills

91007

Site US10006, Arcadia

92260

Site US10007, Palm Desert

92705

Site US10031, Santa Ana

95819

Site US10011, Sacramento

985540

Site US10001, Omaha

02114

Site US10002, Boston

78240-1502

Site US10009, San Antonio

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02302079 - A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter